InvestSMART

Proteomics International Laboratories Ltd (ASX:PIQ)

ALERT: Price-sensitive ASX Announcement for PIQ
Current share price for PIQ : $0.155 0.005 (3.33%)+
Announcement
Release
22 Jul 2026 8:30AM
Price at Release
$0.150
Full Release
download
Summary
Proteomics International Laboratories Ltd has signed a national distribution agreement with Healius Limited, appointing Healius as the exclusive pathology distribution partner for the Promarker® portfolio in Australia. The initial term of this agreement is three years, with an option to extend for an additional three years by mutual agreement. This collaboration grants Proteomics International access to Healius' extensive pathology network, including over 2,000 patient collection centers. While Proteomics International will maintain responsibility for laboratory testing and clinical reporting, Healius will handle the national distribution aspects. The deal marks a significant step in commercializing the Promarker® portfolio, allowing for a phased rollout during the financial year 2027. The agreement's commercial terms remain confidential, with revenue projections currently indeterminable due to the early stage of commercialization.
Key Points
  • Proteomics International signs national distribution agreement with Healius.
  • Healius appointed as exclusive pathology distribution partner for Promarker® portfolio.
  • Initial term of three years, with an option to extend for another three.
  • Provides access to Healius' network of over 2,000 patient collection centers.
  • Proteomics International retains responsibility for testing and reporting.
  • Healius responsible for pathology distribution and market access.
  • Phased commercial rollout planned for FY27.
  • Commercial terms are confidential; revenue estimates currently unavailable.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.